Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.81 |
| ▸ | AKR1B10 | O60218 | 6/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylpropyl Fumarate SCHEMBL3482832 | 1.00 | HCAR2 (0.81) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| Phenylpropyl Fumarate SCHEMBL27216278 | 1.00 | HCAR2 (0.81) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| SCHEMBL8708780 | 0.95 | HCAR2 (0.72) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| SCHEMBL355844 | 0.95 | HCAR2 (0.72) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| SCHEMBL355843 | 0.95 | HCAR2 (0.72) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| SCHEMBL28500283 | 0.94 | HCAR2 (0.77) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| Hydrochloric Acid SCHEMBL27349461 | 0.94 | HCAR2 (0.77) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| Phenylethyl Fumarate SCHEMBL573379 | 0.90 | HCAR2 (1.00) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| Phenylethyl Fumarate SCHEMBL573376 | 0.90 | HCAR2 (1.00) | HCAR2AKR1B10AKR1B1LMNAALOX5 | |
| Phenylethyl Fumarate SCHEMBL27750209 | 0.90 | HCAR2 (1.00) | HCAR2AKR1B10AKR1B1LMNAALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| CN-113453762-A | Pentacyclic heterocyclic compounds | 卫材R&D管理有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-8420764-B2 | Compound having silsesquioxane skeleton and its polymer | JNC CORPORATION (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20120178894-A1 | COMPOUND HAVING SILSESQUIOXANE SKELETON AND ITS POLYMER | INAGAKI JYUN-ICHI (JP) | 2012-07-12 | — | — | US | disclosed |
| US-7705105-B2 | A cyclic polymer of silsesquioxane skeleton with side chains formed byhydrosilation of an unsaturated end group containing an active polymerfunctional group; polyimidesiloxane copolymers; polyestersiloxane copolymers; high molecular weight; thin films; strength; heat resistance;waterproofing; | CHISSO PETROCHEMICAL CORPORATION (JP) | 2010-04-27 | — | — | US | disclosed |
| US-20070190344-A1 | Verification of translation | JNC CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| US-20050009982-A1 | Compound having silsesquioxane skeleton and its polymer | CHISSO CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | CYP2C19, CYP2C18, XDH | HCAR2 996/4885AKR1B10 894/4885AKR1B1 428/4885 |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | CYP2C19, CYP2C18, XDH | HCAR2 996/4885AKR1B10 894/4885AKR1B1 428/4885 |
| US-20050009982-A1 | Compound having silsesquioxane skeleton and its polymer | C1S, H1-4, H1-0 | HCAR2 2928/4885AKR1B10 2310/4885AKR1B1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.